Highlighting Advances in Chondrosarcoma and TGCT Treatment

At the 4th Annual Miami Cancer Institute Precision Oncology Symposium on January 30 to 31, 2026, Neeta Somaiah, MD, professor and department chair in the department of sarcoma medical oncology in the division of cancer medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, highlighted significant advancements in targeted therapies for sarcoma that stood out in the past year. In an interview, she discussed her presentation and focused on 2 practice-changing clinical trials that emerged over the past year that offer new hope for rare cancers that have historically lacked effective treatment options.

Advancements in Advanced Chondrosarcoma

The first breakthrough involves ozekibart (INBRX-109), a tetravalent death receptor 5 (DR5) agonist.¹ Chondrosarcoma, a bone sarcoma subtype, has long frustrated medical oncologists due to its resistance to standard therapies. Ozekibart works by mimicking the TNF-related apoptosis-inducing ligand, binding to DR5 to trigger receptor multimerization and subsequent cell death (apoptosis).

The randomized phase 2 ChonDRAgon study (NCT04950075) evaluated ozekibart against a placebo. Results showed a median progression-free survival (PFS) of 5.5 months for the treatment arm compared with 2.6 months for the placebo group. This represents a 52% reduction in the risk of disease progression or death (HR, 0.479). Given the lack of a current standard of care, these results provide a potential path toward regulatory registration.

Targeting Tenosynovial Giant Cell Tumor (TGCT)

Somaiah also addressed pimicotinib (ABSK021), a CSF1R inhibitor investigated in the phase 3 MANEUVER study (NCT05804045) for tenosynovial giant cell tumor.² This trial demonstrated significant improvements in tumor volume reduction and clinical symptoms, including joint pain, stiffness, and range of motion. Pimicotinib enters a space with existing CSF1R inhibitors, but its specific safety profile may offer a superior alternative for certain patient populations.

REFERENCES

1. Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts. News release. Inhibrx Biosciences. October 23, 2025. Accessed February 2, 2026. https://tinyurl.com/m8k6uurh

2. Niu X, Ravi V, Broto JM, et al. Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study. J Clin Oncol. 2025;43(suppl 16):11500. doi:10.1200/JCO.2025.43.16_suppl.11500